Physician profile
Maurice E Nida
NPI 1285601344
$1,476.82
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $528 · 2021: $242 · 2022: $12.28 · 2023: $62.51 · 2024: $14.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $242.87 | 2019-2021 | |
| Novo Nordisk INC | $141.55 | 2019-2021 | |
| Glaxosmithkline, LLC. | $118.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $116.60 | 2019-2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $115.54 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.09 | 2020-2021 | |
| Amgen INC. | $85.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.63 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $68.12 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $63.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $52.27 | 2019-2021 | |
| Abbvie INC. | $41.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.84 | 2019 | |
| Abbott Laboratories | $37.06 | 2022-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $36.16 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $33.57 | 2020-2021 | |
| Allergan, INC. | $23.02 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.32 | 2023 | |
| Esperion Therapeutics, INC. | $17.91 | 2020 | |
| Genentech USA, INC. | $14.67 | 2019 | |
| Pfizer INC. | $13.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Nida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.